(:HZNP)

Oct 03, 2023 11:15 am ET
Oct 03, 2023 11:06 am ET
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
Horizon Therapeutics plc (NASDAQ: HZNP):
Oct 02, 2023 11:39 am ET
Oct 02, 2023 11:24 am ET
Oct 02, 2023 08:00 am ET
Horizon Therapeutics plc Announces New UPLIZNA® (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be presented at ECTRIMS 2023
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that new UPLIZNA analyses will be presented at the 39th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2023, Oct. 11-13. UPLIZNA is the first and only targeted CD19+ B-cell-depleting therapy approved by the U.S. Food and Drug Administration, the European Commission and the Brazilian Health Regulatory Agency (ANVISA) for the treatment of NMOSD in adults who are anti-aquaporin-4 immunoglobulin G seropositive (AQP4-IgG+).
Sep 29, 2023 11:45 am ET
Sep 29, 2023 10:00 am ET
New Analysis Highlights Importance of Adhering to Uninterrupted Full Course of Treatment with TEPEZZA® (teprotumumab-trbw) to Support Thyroid Eye Disease (TED) Patient Outcomes
Horizon Therapeutics plc (Nasdaq: HZNP) today announced new data showing that disrupting the recommended TEPEZZA treatment regimen by lengthening the amount of time between infusions can increase the need for a second course of treatment. These findings, along with new subgroup data from the TEPEZZA Phase 4 clinical trial in patients with long disease duration and low Clinical Activity Score (CAS) and an analysis of the impact of TED on QOL, were shared at the 92nd Annual Meeting of the American Thyroid Association (
Sep 27, 2023 09:45 am ET
Sep 26, 2023 09:02 am ET
Horizon Therapeutics plc Named to U.S. News & World Report’s 2024 List of Best Companies to Work For in the Health Care Industry
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been named to U.S. News & World Report’s 2024 list of Best Companies to Work For in the Health Care Industry, ranking among the top companies recognized for employee wellbeing.
Sep 25, 2023 09:34 am ET
Sep 19, 2023 08:00 am ET
Horizon Therapeutics plc Ranks Number One on the Fortune Best Workplaces in Biopharma 2023 List
Horizon Therapeutics plc (Nasdaq: HZNP) announced it has been named No. 1 on the Fortune Best Workplaces in Biopharma 2023 list in the large company category. This is the seventh consecutive year Horizon has been named to the list and the company’s fourth time ranking No. 1.
Sep 13, 2023 08:00 am ET
Sep 13, 2023 08:00 am ET
Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of Bempikibart (formerly ADX-914) for Severe Alopecia Areata
Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, and Horizon Therapeutics plc (Nasdaq: HZNP), today announced that the first patient has been dosed in a randomized, double-blind, placebo-controlled, Phase 2 multicenter, proof-of-concept study to evaluate bempikibart in adult patients with severe al
Sep 06, 2023 04:15 pm ET
Horizon Therapeutics plc (“Horizon”) Rule 2.12 Announcement
In accordance with Rule 2.12 of the Irish Takeover Panel Act, 1997, Takeover Rules, 2022 (the “Irish Takeover Rules”), Horizon confirms that, as of the close of business on September 5, 2023, Horizon’s issued ordinary share capital is comprised of 229,214,753 ordinary shares, nominal value $0.0001 per share (the “Ordinary Shares”) and 40,000 deferred ordinary shares of €1.00 each. The Company has 384,366 Ordinary Shares which are held as treasury shares. The Ordinary Shares are admitted to trading on the Nasdaq Global Select Market under the ticker symbol “HZ
Sep 05, 2023 09:05 am ET
Horizon Therapeutics Announces Date of Irish Court Hearing to Sanction Scheme of Arrangement
Horizon Therapeutics plc, a public limited company incorporated in Ireland ("Horizon" or the "Company") announces today that, in relation to the offer for the Company by Pillartree Limited ("Acquirer Sub"), a private limited company wholly owned by Amgen Inc., a Delaware corporation ("Amgen"), pursuant to which Acquirer Sub will acquire the entire issued and to be issued ordinary share capital of the Company (the "Proposed Transaction") pursuant to a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act 2014 (the "Scheme"), that the Irish High Court (the "Court") has set t
Sep 01, 2023 09:20 am ET
Amgen and Horizon Therapeutics plc Resolve FTC Lawsuit, Clearing Path to Close Acquisition
Amgen (NASDAQ:AMGN) and Horizon Therapeutics plc (NASDAQ:HZNP) today announced the entry into a consent order agreement with the Federal Trade Commission (FTC) that resolves the pending FTC administrative lawsuit. This clears the path to take the final steps to close Amgen’s acquisition of Horizon.
Aug 23, 2023 08:00 am ET
Horizon Therapeutics plc Ranks First in Overall Corporate Reputation by Rare Disease Patient Advocacy Groups
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it ranked first in overall corporate reputation among rare disease patient groups around the world who were familiar with the company. Rare disease patient groups who worked with Horizon also ranked the company first in 10 of the 14 indicators including patient centricity, patient information, integrity, access to medicines, relationships (communications, long-term support and ease of working) and services “beyond the pill.” The results are based on PatientView’s 2022 global “Corporate Reputation of Pharma” survey of 426 patient grou
Aug 09, 2023 10:30 am ET
Horizon Therapeutics plc - Rule 2.12 Announcement
In accordance with Rule 2.12 of the Irish Takeover Panel Act, 1997, Takeover Rules, 2022 (the “Irish Takeover Rules”), Horizon confirms that, as of the close of business on June 30, 2023, Horizon’s issued ordinary share capital is comprised of 228,939,027 ordinary shares, nominal value $0.0001 per share (the “Ordinary Shares”) and 40,000 deferred ordinary shares of €1.00 each. The Company has 384,366 Ordinary Shares which are held as treasury shares. The Ordinary Shares are admitted to trading on the Nasdaq Global Select Market under the ticker symbol “HZNP”.
Aug 08, 2023 07:00 am ET
Horizon Therapeutics plc Reports Second-Quarter 2023 Financial Results
Horizon Therapeutics plc (Nasdaq: HZNP) today announced second-quarter 2023 financial results.
Jul 28, 2023 11:55 am ET
Jul 28, 2023 11:45 am ET
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
Horizon Therapeutics plc (NASDAQ: HZNP):
Jul 28, 2023 11:35 am ET
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
Horizon Therapeutics plc (NASDAQ: HZNP):
Jul 28, 2023 11:30 am ET
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
Horizon Therapeutics plc (NASDAQ: HZNP):
Jul 28, 2023 11:20 am ET
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
Horizon Therapeutics plc (NASDAQ: HZNP):
Jul 28, 2023 11:15 am ET
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
Horizon Therapeutics plc (NASDAQ: HZNP):
Jul 28, 2023 11:05 am ET
Jul 28, 2023 10:55 am ET
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
Horizon Therapeutics plc (NASDAQ: HZNP):
Jul 27, 2023 08:00 am ET
Horizon Therapeutics plc Announces 2023 #RAREis Global Advocate Grant Recipients
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the 50 awardees from around the world selected to receive the 2023 #RAREis™ Global Advocate Grant. These rare disease patient advocacy organizations will receive a one-time grant of $5,000 to establish new programs, develop educational resources and expand their current offerings to support their disease communities.
Jul 21, 2023 04:30 pm ET
Horizon Therapeutics plc Announces Phase 2 Trial Evaluating Daxdilimab for the Treatment of Systemic Lupus Erythematosus (SLE) Did Not Meet Primary Endpoint
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that its Phase 2 clinical trial evaluating daxdilimab for the treatment of SLE did not show a statistically significant separation between daxdilimab and placebo on the primary endpoint, which was the proportion of patients to achieve a British Isles Lupus Assessment Group (BILAG) 2004 Index-based Combined Lupus Assessment (BICLA) response and an oral glucocorticoid (OGC) dose of ≤7.5 mg/day (prednisone equivalent), which represented a reduction from the Baseline OGC dose at 48 weeks. BICLA is a composite measure indicating low SLE diseas
Jul 17, 2023 08:00 am ET
Horizon Therapeutics plc to Release Second-Quarter 2023 Financial Results on Aug. 8, 2023
Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it will release its second-quarter 2023 financial results on Tuesday, Aug. 8, 2023, prior to the open of the U.S. financial markets.
Jul 06, 2023 08:00 am ET
Long-Term Data From the MIRROR Randomized Controlled Trial of KRYSTEXXA® (pegloticase) Injection With Methotrexate Published in ACR Open Rheumatology
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the publication of the long-term data from the MIRROR randomized controlled clinical trial of KRYSTEXXA® (pegloticase) injection with methotrexate, a commonly used immunomodulator, in ACR Open Rheumatology [https://doi.org/10.1002/acr2.11578
Jun 30, 2023 12:30 pm ET
New Analysis of MRI Findings Shows UPLIZNA® (inebilizumab-cdon) Reduced the Formation of Subclinical Spinal Cord Lesions in People With Neuromyelitis Optica Spectrum Disorder (NMOSD)
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the presentation of a new analysis of MRI data from the Phase 3 clinical trial of UPLIZNA showing a reduction in the formation of subclinical (asymptomatic) transverse myelitis lesions in people with NMOSD. This analysis is being presented at the 9th Congress of the European Academy of Neurology (EAN), July 1-4 in Budapest.
Jun 26, 2023 11:00 am ET
TEPEZZA® (teprotumumab) Approved in Brazil for the Treatment of Active Thyroid Eye Disease (TED)
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the Brazilian Health Regulatory Agency (ANVISA) has approved TEPEZZA for the treatment of active TED. TEPEZZA is the first and only medicine approved for active TED in Brazil, filling a significant unmet need for those who are living with this progressive autoimmune disease that can threaten vision.
Jun 22, 2023 08:00 am ET
Horizon Therapeutics plc Announces Positive Topline Data from Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating TEPEZZA® (teprotumumab-trbw) for the Treatment of Active Thyroid Eye Disease (TED)
Horizon Therapeutics plc (Nasdaq: HZNP) today announced positive topline results from its randomized, double-masked, placebo-controlled Phase 3 clinical trial evaluating TEPEZZA for the treatment of TED in Japanese patients with higher levels of disease activity, as measured by clinical activity score (CAS). TED is a serious, progressive, debilitating and potentially vision-threatening rare autoimmune disease that can cause proptosis (eye bulging), diplopia (double vision), eye pain, redness and swelling.1
Jun 17, 2023 05:00 pm ET
Additional Data from Phase 4 TEPEZZA® (teprotumumab-trbw) Clinical Trial Presented at the Endocrine Society Annual Meeting Reinforces Efficacy in People with Thyroid Eye Disease (TED) Regardless of Di
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the presentation of new data from the randomized, double-masked, placebo-controlled Phase 4 clinical trial (NCT04583735) evaluating TEPEZZA in patients with long disease duration and low Clinical Activity Score (CAS), a measure of dise
Jun 17, 2023 02:00 pm ET
New Data from TEPEZZA® (teprotumumab-trbw) Clinical Trials and Real-World Analyses Shed Light on Link Between Thyroid Autoimmunity and Hearing Risks
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the presentation of a series of analyses demonstrating the risk of hearing-related events among people with Graves’ disease and TED, including among those treated with TEPEZZA. TEPEZZA is the first and only medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of TED, regardless of disease activity or duration. TED is a serious, progressive and potentially vision-threatening rare autoimmune disease.1
Jun 12, 2023 07:00 pm ET
Horizon Therapeutics plc (“Horizon”) Rule 2.12 Announcement
In accordance with Rule 2.12 of the Irish Takeover Panel Act, 1997, Takeover Rules, 2022 (the “Irish Takeover Rules”), Horizon confirms that, as of the close of business on June 9, 2023, Horizon’s issued ordinary share capital is comprised of 228,928,661 ordinary shares, nominal value $0.0001 per share (the “Ordinary Shares”) and 40,000 deferred ordinary shares of €1.00 each. The Company has 384,366 Ordinary Shares which are held as treasury shares. The Ordinary Shares are admitted to trading on the Nasdaq Global Select Market under the ticker symbol “HZNP”. The Internatio
Jun 12, 2023 08:00 am ET
UPLIZNA® (inebilizumab-cdon) Pivotal Trial Publication Integrating MRI and Biomarker Evaluation Shows Accuracy and Uniformity of Attack Diagnoses for Neuromyelitis Optica Spectrum Disorder (NMOSD)
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the publication of a new analysis from the N-MOmentum clinical trial of UPLIZNA demonstrating the utility of a robust adjudication process that could improve clinical care decision-making in neuromyelitis optica spectrum disorder (NMOSD) through more accurate and consistent assessment of disease-related attacks. These findings are published in the
Jun 06, 2023 07:00 am ET
Horizon Therapeutics plc announces premium partnership with KPMG Women’s Irish Open
Horizon Therapeutics plc (Nasdaq: HZNP) today announced its partnership for the 2023 KPMG Women’s Irish Open held at Dromoland Castle from August 31 to September 3. The leading Ladies European Tour (LET) event tees up a week prior to the Horizon Irish Open and will draw Europe's leading professional female golfers who will go head to head for a total prize fund of €400,000.
Jun 05, 2023 08:00 am ET
Horizon Therapeutics plc Announces Data from the TEPEZZA® (teprotumumab-trbw) Phase 4 Clinical Trial in Patients with Chronic/Low CAS Thyroid Eye Disease (TED) to be Presented at the Upcoming Endocrin
Horizon Therapeutics plc (Nasdaq: HZNP) today announced new data will be presented at the annual meeting of the Endocrine Society (ENDO 2023) in Chicago, June 15-18. TEPEZZA is the first and only medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of Thyroid Eye Disease (TED) regardless of disease activity or duration. TED is a serious, progressive, debilitating and potentially vision-threatening rare autoimmune disease.1
Jun 02, 2023 11:50 am ET
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
Horizon Therapeutics plc (NASDAQ: HZNP):
Jun 02, 2023 11:40 am ET
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
Horizon Therapeutics plc (NASDAQ: HZNP):
Jun 02, 2023 11:30 am ET
Jun 01, 2023 08:00 am ET
Biomarker Analysis Publication Highlights Key Signals of Disability Worsening Associated With Neuromyelitis Optica Spectrum Disorder (NMOSD) Attacks, Illustrates Efficacy of UPLIZNA® (inebilizumab-cdo
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the publication of new data from the Phase 3 N-MOmentum pivotal trial of UPLIZNA, which offer insights on serum biomarkers that signal acute attacks and disability worsening associated with NMOSD and illustrate the role of UPLIZNA in reducing these biomarker levels, potentially reducing the frequency and severity of these attacks. The results of this analysis are published in
May 31, 2023 08:10 am ET
Presentations at the 2023 EULAR European Congress of Rheumatology Highlight New Results from Phase 2 Trial Evaluating Dazodalibep in Sjögren’s Syndrome
Horizon Therapeutics plc (Nasdaq: HZNP) today announced presentations of new results from the randomized, double-blind, placebo-controlled Phase 2 trial showing dazodalibep, an investigational treatment for Sjögren’s syndrome, may improve some of the most prominent effects of this chronic, systemic autoimmune condition characterized by inflammation of exocrine glands. These are the first presentations of the Phase 2 trial results and are part of expert dialogue this week at the
May 31, 2023 08:00 am ET
New Analyses of the MIRROR Randomized Controlled Trial in Uncontrolled Gout Presented at the 2023 EULAR European Congress of Rheumatology
Horizon Therapeutics plc (Nasdaq: HZNP) today announced new analyses from the MIRROR randomized controlled trial of KRYSTEXXA® (pegloticase) injection with methotrexate show a multi-faceted impact when treating adults living with chronic gout refractory to oral therapy, or uncontrolled gout. Presentations are part of expert discussions at the
May 23, 2023 08:00 am ET
Horizon Therapeutics plc Announces Presentation of Data that Advances the Understanding of Rheumatic Diseases at the 2023 EULAR European Congress of Rheumatology
Horizon Therapeutics plc (Nasdaq: HZNP) today announced plans for the first presentation of data from a Phase 2 study of dazodalibep, the company’s investigational therapy for Sjögren’s syndrome, during the 2023 EULAR European Congress of Rheumatology, May 31 - June 3, 2023, in Milan. The company will also pres
May 16, 2023 11:46 am ET
Horizon Therapeutics plc Responds to U.S. Federal Trade Commission (FTC) Action to Block Acquisition by Amgen
Horizon Therapeutics plc (Nasdaq: HZNP) today issued the following statement in response to the FTC’s complaint seeking to block Amgen’s proposed acquisition of the Company:
May 10, 2023 11:30 am ET
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
Horizon Therapeutics plc (NASDAQ: HZNP):
May 09, 2023 08:00 am ET
Horizon Therapeutics plc Ranks First in Overall Corporate Reputation by U.S. Patient Advocacy Groups
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it ranked first in overall corporate reputation among U.S. patient groups who reported working with, or who were familiar with the company. The results are based on PatientView’s annual survey of 361 patient groups who evaluated 41 pharmaceutical and biotechnology companies across 14 individual indicators.
May 04, 2023 04:35 pm ET
 Horizon Therapeutics plc (“Horizon”) - Rule 2.12 Announcement
In accordance with Rule 2.12 of the Irish Takeover Panel Act, 1997, Takeover Rules, 2022 (the “Irish Takeover Rules”), Horizon confirms that, as of the close of business on March 31, 2023, Horizon’s issued ordinary share capital is comprised of 228,576,339 ordinary shares, nominal value $0.0001 per share (the “Ordinary Shares”) and 40,000 deferred ordinary shares of €1.00 each. The Company has 384,366 Ordinary Shares which are held as treasury shares. The Ordinary Shares are admitted to trading on the Nasdaq Global Select Market under the ticker symbol “HZNP”. The Internat
May 03, 2023 07:00 am ET
Horizon Therapeutics plc Reports First-Quarter 2023 Financial Results
Horizon Therapeutics plc (Nasdaq: HZNP) today announced first-quarter 2023 financial results.
May 02, 2023 09:25 am ET
Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab for the Treatment of Lupus Nephritis
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the first patient has enrolled in a Phase 2 randomized placebo-controlled trial to evaluate its development-stage medicine daxdilimab, a potentially first-in-class, fully human monoclonal antibody targeting immunoglobulin-like transcript 7 (ILT7) that depletes certain dendritic cells, to treat people with active proliferative lupus nephritis (LN).
May 02, 2023 08:00 am ET
Horizon Therapeutics plc Ranks First in Patient Centricity and Integrity by Patient Advocacy Groups According to New PatientView Survey
Horizon Therapeutics plc (Nasdaq: HZNP) today announced it ranked first in patient centricity, integrity, ease of relations and transparency in pricing by patient groups who worked with the company around the world. It ranks second in overall corporate reputation among these same groups. The results are based on PatientView’s annual survey of more than 2,200 patient groups evaluating more than 40 biotechnology and pharmaceutical companies.
May 01, 2023 11:59 am ET
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
Horizon Therapeutics plc (NASDAQ: HZNP):
May 01, 2023 11:55 am ET
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
Horizon Therapeutics plc (NASDAQ: HZNP):
May 01, 2023 11:50 am ET
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
Horizon Therapeutics plc (NASDAQ: HZNP):
May 01, 2023 11:46 am ET
May 01, 2023 11:45 am ET
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
Horizon Therapeutics plc (NASDAQ: HZNP):
May 01, 2023 11:42 am ET
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
Horizon Therapeutics plc (NASDAQ: HZNP):
May 01, 2023 11:37 am ET
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
Horizon Therapeutics plc (NASDAQ: HZNP):
May 01, 2023 11:35 am ET
May 01, 2023 08:00 am ET
Horizon Therapeutics plc Announces Initiation of Phase 3 Clinical Trial in Japan Evaluating TEPEZZA® (teprotumumab-trbw) in Adults with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (T
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the first patient has been enrolled in a Phase 3 clinical trial in Japan evaluating TEPEZZA for the treatment of adults with chronic Thyroid Eye Disease (TED) and low clinical activity score (CAS), which is a measure of disease activity. The trial includes patients with an initial diagnosis of TED between two to 10 years prior to the study and low levels of disease activity. Findings from this study will build on a separate Phase 3 clinical trial (OPTIC-J) that is currently underway in Japan and is evaluating TEPEZZA for the treatmen
Apr 20, 2023 08:00 am ET
Horizon Therapeutics plc Announces UPLIZNA® (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be Presented at the 2023 American Academy of Neurology (AAN) Annual Meeting
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that multiple UPLIZNA analyses will be presented at the 2023 American Academy of Neurology (AAN) Annual Meeting, April 22-27 in Boston. UPLIZNA is the first and only anti-CD19 B-cell-depleting humanized monoclonal antibody approved by the U.S. Food and Drug Administration (FDA), European Commission (EC) and Brazilian Health Regulatory Agency (ANVISA) for the treatment of NMOSD in adults who are anti-aquaporin-4-immunoglobulin G seropositive (AQP4-IgG+).
Apr 18, 2023 08:00 am ET
Horizon Therapeutics plc and Massachusetts Institute of Technology (MIT) Solve Announce the Launch of the Third Annual Horizon Prize to Inspire Sustainable Solutions for Research and Care in the Rare
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the launch of the third annual global innovation challenge, The Horizon Prize, powered by MIT Solve.
Apr 17, 2023 08:08 am ET
Horizon Therapeutics Announces Date of Irish Court Hearing to Sanction Scheme of Arrangement
Horizon Therapeutics plc, a public limited company incorporated in Ireland ("Horizon" or the "Company") announces today that, in relation to the offer for the Company by Pillartree Limited ("Acquirer Sub"), a private limited company wholly owned by Amgen Inc., a Delaware corporation ("Amgen"), pursuant to which Acquirer Sub will acquire the entire issued and to be issued ordinary share capital of the Company (the "Proposed Transaction") pursuant to a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act 2014 (the "Scheme"), that th
Apr 14, 2023 08:15 am ET
Horizon Therapeutics plc Announces FDA Approval of an Update to the Indication Language for TEPEZZA® (teprotumumab-trbw) to Specify its Use in Thyroid Eye Disease (TED) Patients Regardless of Disease
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the U.S. Food and Drug Administration (FDA) has approved an update to the Indications and Usage section of the TEPEZZA label to specify its use for the treatment of “Thyroid Eye Disease regardless of Thyroid Eye Disease activity or duration.” TEPEZZA is the first and only medicine approved by the FDA for the treatment of TED – a serious, progressive, debilitating and potentially vision-threatening rare autoimmune disease.1
Apr 14, 2023 08:00 am ET
Horizon Therapeutics plc to Release First-Quarter 2023 Financial Results on May 3, 2023
Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it will release its first-quarter 2023 financial results on Wednesday, May 3, 2023, prior to the open of the U.S. financial markets.
Apr 10, 2023 08:00 am ET
Horizon Therapeutics plc Announces Positive Topline Data from TEPEZZA® (teprotumumab-trbw) Phase 4 Clinical Trial in Patients with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED)
Horizon Therapeutics plc (Nasdaq: HZNP) today announced positive and statistically significant topline results from its randomized, double-masked, placebo-controlled Phase 4 clinical trial (NCT04583735) evaluating TEPEZZA for the treatment of adults with chronic TED and low CAS, which is a
Apr 04, 2023 08:00 am ET
Horizon Therapeutics plc Named to the 2023 Fortune 100 Best Companies to Work For List
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been named one of Fortune’s 100 Best Companies to Work For® for the third consecutive year.
Mar 16, 2023 11:55 am ET
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
Horizon Therapeutics plc (NASDAQ: HZNP):
Mar 14, 2023 11:15 am ET
New Analysis of MRI Findings Show UPLIZNA® (inebilizumab-cdon) Reduced the Formation of Asymptomatic Optic Nerve Lesions in People With Neuromyelitis Optica Spectrum Disorder (NMOSD)
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the presentation of new MRI imaging data from the Phase 3 clinical trial showing UPLIZNA reduced the formation of subclinical (asymptomatic) optic nerve lesions in people with NMOSD. These findings are being presented during the 49th annual meeting of the North American Neuro-Ophthalmology Society (
Mar 12, 2023 12:00 pm ET
Real-World Experience Shows TEPEZZA® (teprotumumab-trbw) Was Effective in Treating People With Dysthyroid Optic Neuropathy (DON)
Horizon Therapeutics plc (Nasdaq: HZNP) today announced results of an analysis of real-world treatment with TEPEZZA in Thyroid Eye Disease (TED) patients with DON, the majority of whom had not previously responded to other treatments. DON is a complication of TED characterized by thyroid-related impairment of visual function and can lead to permanent sight loss related to optic nerve compression.1 TEPEZZA is the first and only medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of TED – a serious, progressive and potentially vision-threatening rare aut
Mar 01, 2023 04:05 pm ET
Horizon Therapeutics plc - Rule 2.12 Announcement
In accordance with Rule 2.12 of the Irish Takeover Panel Act, 1997, Takeover Rules, 2022 (the “Irish Takeover Rules”), Horizon confirms that, as of the close of business on February 23, 2023, Horizon’s issued ordinary share capital is comprised of 228,832,390 ordinary shares, nominal value $0.0001 per share (the “Ordinary Shares”) and 40,000 deferred ordinary shares of €1.00 each. The Company has 384,366 Ordinary Shares which are held as treasury shares. The Ordinary Shares are admitted to trading on the Nasdaq Global Select Market under the ticker symbol “HZNP”. The Inter
Mar 01, 2023 07:02 am ET
Horizon Therapeutics plc Reports Fourth-Quarter and Full-Year 2022 Financial Results
Horizon Therapeutics plc (Nasdaq: HZNP) today announced fourth-quarter and record full-year 2022 financial results.
Feb 28, 2023 08:00 am ET
Horizon Therapeutics plc Opens Applications for #RAREis Global Advocate Grant Program
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that applications for its 2023 #RAREis Global Advocate Grant are open through March 31, 2023. To increase impact and support advocates who are catalysts for rare disease community needs, #RAREis will grant 50 groups with a one-time $5,000 grant. In 2022, the company awarded 30 grants to advocacy organizations.
Feb 24, 2023 04:05 pm ET
Feb 23, 2023 08:00 am ET
New Data Suggest UPLIZNA® (inebilizumab-cdon) for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD) Did Not Increase the Risk of COVID-19 Infection or Reduce Antibody Levels From Childho
Horizon Therapeutics plc (Nasdaq: HZNP) today announced new data from two post-hoc analyses of the N-MOmentum clinical trial of UPLIZNA for the treatment of neuromyelitis optica spectrum disorder (NMOSD) will be presented at the eighth annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum, February 23-25, 2023, in San
Jan 30, 2023 08:00 am ET
Horizon Therapeutics plc to Release Fourth-Quarter and Full-Year 2022 Financial Results on March 1, 2023
Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it will release its fourth-quarter and full-year 2022 financial results on Wednesday, March 1, 2023, prior to the open of U.S. financial markets.
Jan 27, 2023 04:05 pm ET
Rule 15 (c) Announcement – Horizon Therapeutics plc
Horizon Therapeutics plc (NASDAQ: HZNP):
Jan 26, 2023 12:15 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HZNP, COUP, MLVF, TCFC
NEW YORK, Jan. 26, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Jan 25, 2023 04:00 pm ET
ALERT: The M&A Class Action Firm Continues Investigating the Merger – HZNP, ANGN, TIG, CNCE
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered...
Jan 25, 2023 01:05 pm ET
HORIZON THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Horizon Therapeutics Public Limit
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Horizon Therapeutics Public Limited Company (NasdaqGS: HZNP) to Amgen Inc. (NasdaqGS: AMGN). Under the terms of the proposed transaction, shareholders of Horizon will receive only $116.50 in cash for each share of Horizon that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Jan 23, 2023 06:05 pm ET
Rule 17 (b) Announcement – Horizon Therapeutics plc
On December 12, 2022, the board of directors of Horizon Therapeutics plc, a public limited company incorporated in Ireland (the “Company” or “Horizon”) and the board of directors of Amgen Inc., a Delaware corporation (“Amgen”), announced that they had reached agreement on the terms of a cash offer for the Company by Pillartree Limited, a newly formed private limited company wholly owned by Amgen (“Acquirer Sub”), pursuant to which Acquirer Sub will acquire the entire issued and to be issued ordinary share capital of the Company (the “Proposed Transaction”). A
Jan 23, 2023 06:01 pm ET
Rule 17 (a) Announcement – Horizon Therapeutics plc
Horizon Therapeutics plc (NASDAQ: HZNP):
Jan 22, 2023 10:03 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates IMRA, AGFS, SAL, HZNP
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Imara Inc. (NASDAQ: IMRA)’s merger...
Jan 19, 2023 10:00 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SAL, HZNP, COUP, TCFC
NEW YORK, Jan. 19, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Jan 18, 2023 04:00 pm ET
SHAREHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – APEN, HZNP, PSBP, TIG
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered...
Jan 18, 2023 08:00 am ET
Horizon Therapeutics plc Announces Phase 2 Trial Evaluating Dazodalibep for the Treatment of Sjögren’s Syndrome Meets Primary Endpoint in the Second Study Population; Only Phase 2 Trial to Meet Primar
Today, the Company announced that the second population achieved the primary endpoint. This patient population includes those with moderate-to-severe symptomatology including dryness, pain and fatigue despite lacking additional organ involvement and is defined as patients with a European Alliance of Associations for Rheumatology (EULAR) Sjögren’s Syndrome Patient Reported Index (ESSPRI) score of ≥ 5, indicative of significant symptomatic burden, and a score of
Jan 12, 2023 05:05 pm ET
Rule 2.12 Announcement – Horizon Therapeutics plc
In accordance with Rule 2.12 of the Irish Takeover Panel Act, 1997, Takeover Rules, 2022 (the “Irish Takeover Rules”), Horizon confirms that, as of the close of business on January 11, 2023, Horizon’s issued ordinary share capital is comprised of 228,768,464 ordinary shares, nominal value $0.0001 per share (the “Ordinary Shares”) and 40,000 deferred ordinary shares of €1.00 each. The Company has 384,366 Ordinary Shares which are held as treasury shares. The Ordinary Shares are admitted to trading on the Nasdaq Global Select Market under the ticker symbol “HZNP”. The Intern
Jan 12, 2023 09:40 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SAL, HZNP, TIG, QUMU
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Salisbury Bancorp, Inc. (NASDAQ:...
Jan 11, 2023 04:00 pm ET
SHAREHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – KNBE, PSBP, HZNP, TIG
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered...
Jan 10, 2023 10:15 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SAFE, BNFT, HZNP
NEW YORK, Jan. 10, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Jan 06, 2023 11:55 am ET
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
Horizon Therapeutics plc (NASDAQ: HZNP):
Jan 06, 2023 11:45 am ET
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
Horizon Therapeutics plc (NASDAQ: HZNP):
Jan 06, 2023 11:41 am ET
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
Horizon Therapeutics plc (NASDAQ: HZNP):
Jan 06, 2023 11:25 am ET
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
Horizon Therapeutics plc (NASDAQ: HZNP):
Jan 05, 2023 06:39 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates APEN, HZNP, MLVF, TCFC
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Apollo Endosurgery, Inc. (NASDAQ:...
Jan 04, 2023 04:00 pm ET
SHAREHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – TIG, QUMU, HZNP, PSBP
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and...
Jan 04, 2023 11:30 am ET
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
Horizon Therapeutics plc (NASDAQ: HZNP):
Jan 04, 2023 08:00 am ET
Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab for the Treatment of Discoid Lupus Erythematosus
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the first patient has enrolled in a Phase 2, randomized, placebo-controlled trial to evaluate its development-stage medicine daxdilimab, a potentially first-in-class, fully human monoclonal antibody targeting anti-ILT7 depletes certain dendritic cells to treat people with moderate-to-severe primary discoid lupus erythematosus (DLE).
Jan 03, 2023 12:03 pm ET
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
Horizon Therapeutics plc (NASDAQ: HZNP):
Jan 03, 2023 11:58 am ET
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
Horizon Therapeutics plc (NASDAQ: HZNP):
Jan 03, 2023 10:05 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates APEN, HZNP, SESN
NEW YORK, Jan. 3, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Dec 29, 2022 09:25 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates APEN, SAL, HZNP, COUP
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Apollo Endosurgery, Inc. (NASDAQ:...
Dec 28, 2022 03:51 pm ET
ALERT: The M&A Class Action Firm Launches Legal Inquiry Regarding the Merger – HZNP, COUP, PSBP, WEBR
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and...
Dec 28, 2022 09:43 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HZNP, MLVF, TCFC, SHBI
NEW YORK, Dec. 28, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Dec 23, 2022 09:30 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HZNP, IMRA
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Horizon Therapeutics plc (NASDAQ:...
Dec 20, 2022 11:58 am ET
INVESTOR ALERT: The M&A Class Action Firm Launches Legal Inquiry Regarding the Merger – ELVT, HZNP, LBC, COUP
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered...
Dec 20, 2022 08:00 am ET
UPLIZNA® (inebilizumab-cdon) Approved in Brazil for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the Brazilian Health Regulatory Agency (ANVISA) has approved UPLIZNA as a monotherapy for the treatment of adult patients with NMOSD who are AQP4-IgG+. This rare autoimmune disease is caused by inflammation in the central nervous system, resulting in severe and recurrent attacks that can lead to permanent disability, such as paralysis and vision loss.1 An estimated 10,000 people in Brazil live with the disease.2
Dec 20, 2022 02:04 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates STAR, HZNP, COUP, USER
NEW YORK, Dec. 20, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Dec 18, 2022 05:30 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HZNP, COUP, FRBA, MLVF
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Horizon Therapeutics plc (NASDAQ:...
Dec 17, 2022 08:11 pm ET
Lifshitz Law PLLC Announces Investigations of WEBR, COUP, HZNP, and APEN
Weber Inc. (NYSE: WEBR) Lifshitz Law PLLC announces investigation into possible breach of fiduciary duties in connection with the sale of WEBR to affiliates of BDT Capital Partners LLC for $8.05 per share. If you are a WEBR investor, and would...
Dec 13, 2022 07:11 pm ET
HORIZON THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Horizon Therapeutics Public Limit
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Horizon Therapeutics Public Limited Company (NasdaqGS: HZNP) to Amgen Inc. (NasdaqGS: AMGN). Under the terms of the proposed transaction, shareholders of Horizon will receive only $116.50 in cash for each share of Horizon that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Dec 13, 2022 10:04 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HZNP, COUP, WEBR
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Horizon Therapeutics plc (NASDAQ:...
Dec 13, 2022 09:25 am ET
Dec 12, 2022 05:06 pm ET
SHAREHOLDER ALERT: Weiss Law Investigates Horizon Therapeutics Public Limited Company
NEW YORK, Dec. 12, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Horizon Therapeutics Public Limited Company ("Horizon Therapeutics" or the "Company") (NASDAQ: HZNP) in connection with the proposed acquisition of the Company by Amgen Inc. (NASDAQ: AMGN).  Under the terms of the merger agreement, the Company's shareholders will receive $116.50 in cash for each share of Horizon Therapeutics common stock owned.
Dec 12, 2022 02:00 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HZNP, COUP, WEBR
NEW YORK, Dec. 12, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Dec 12, 2022 10:19 am ET
HZNP Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Horizon Therapeutics plc Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Horizon Therapeutics plc (NASDAQ: HZNP) to Amgen Inc. for $116.50 in cash per share is fair to Horizon shareholders.
Dec 12, 2022 08:32 am ET
Thinking about trading options or stock in Horizon Therapeutics, Nvidia, Tesla, Boeing, or Costco?
NEW YORK, Dec. 12, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for HZNP, NVDA, TSLA, BA, and COST.
Dec 12, 2022 06:00 am ET
Rule 2.7 Announcement: Amgen Inc to Acquire Horizon Therapeutics plc
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION
Dec 08, 2022 08:00 am ET
Horizon Therapeutics plc Announces First Subject Dosed in Phase 1 Trial Evaluating HZN-457 for the Treatment of Gout
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the first subject has been dosed in a Phase 1 randomized, placebo-controlled trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of its development-stage medicine HZN-457, previously known as ARO-XDH. HZN-457 is a small interfering RNA (siRNA) candidate designed to treat gout by silencing liver xanthine dehydrogenase. The development of HZN-457 is part of a global collaboration and license agreement that the Company entered in 2021 with Arrowhead Pharmaceuticals (Nasdaq: ARWR).
Nov 30, 2022 08:36 am ET
Thinking about trading options or stock in Horizon Therapeutics, Alibaba, State Street, NetEase, or Crowdstrike?
NEW YORK, Nov. 30, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for HZNP, BABA, STT, NTES, and CRWD.
Nov 29, 2022 04:25 pm ET
Horizon Therapeutics plc Confirms Preliminary Discussions Regarding Potential Offer
The Board of Horizon Therapeutics plc (Nasdaq: HZNP) (“Horizon” or the “Company”) confirms that it is engaged in highly preliminary discussions with Amgen Inc., Janssen Global Services, LLC and Sanofi (each a "Possible Offeror") which may or may not lead to an offer being made for the entire share capital of the Company. There can be no certainty that any offer will be made for the Company.
Nov 16, 2022 08:15 am ET
Horizon Therapeutics plc Announces Completion of Enrollment of Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating TEPEZZA® (teprotumumab-trbw) for the Treatment of Active Thyroid Eye Disease (TED)
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has completed enrollment of its Phase 3 clinical trial (OPTIC-J) in Japan evaluating TEPEZZA for the treatment of active Thyroid Eye Disease (TED).
Nov 16, 2022 08:00 am ET
Horizon Therapeutics plc Announces Scientific Collaboration with Leading Research Institution to Advance Research in Autoimmunity and Inflammation
Horizon Therapeutics plc today announced that it has entered a multi-year scientific collaboration with Johns Hopkins University School of Medicine to identify new disease targets and develop therapies for patients with serious autoimmune and inflammatory conditions. The initial focus is the emerging field of immunometabolism, the st
Nov 10, 2022 08:00 am ET
Horizon Therapeutics plc to Participate in Upcoming Investor Healthcare Conferences in November
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Company will participate in the following conferences in November:
Nov 08, 2022 10:00 am ET
Sustained Patient Response to KRYSTEXXA® (pegloticase) Injection with Methotrexate Compared to KRYSTEXXA Alone Shown through Month 12 in MIRROR Randomized Controlled Trial
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that Month 12 data from the MIRROR randomized controlled trial of KRYSTEXXA® (pegloticase) injection with methotrexate will be featured in Plenary I as part of the American College of Rheumatology Convergence 2022. Additional present
Nov 05, 2022 10:00 am ET
Data Support the Use of KRYSTEXXA® (pegloticase) Injection with Methotrexate to Treat Uncontrolled Gout in People With Mild-to-Moderate Chronic Kidney Disease
Horizon Therapeutics plc (Nasdaq: HZNP) today announced new data that indicate KRYSTEXXA (pegloticase) injection with weekly oral methotrexate effectively treats uncontrolled gout without compromising kidney function. These findings are presented as part of the American Society of Nephrology (ASN) Kidney W
Nov 02, 2022 07:00 am ET
Horizon Therapeutics plc Reports Third-Quarter 2022 Financial Results; Increases Full-Year 2022 Net Sales and Adjusted EBITDA Guidance; Increases TEPEZZA and KRYSTEXXA Peak Annual Net Sales Expectatio
Horizon Therapeutics plc (Nasdaq: HZNP) today announced third-quarter 2022 financial results and increased its full-year 2022 net sales and adjusted EBITDA guidance.
Nov 01, 2022 09:00 am ET
Horizon Therapeutics plc Named to the Seramount Inclusion Index
Horizon Therapeutics plc (Nasdaq: HZNP) today announced it has been named to Seramount’s (formerly Working Mother media) 2022 Inclusion Index. The Inclusion Index recognizes companies that commit to advancing diversity, equity and inclusion (DEI) and implement programming that supports an inclusive workplace.
Oct 27, 2022 08:30 am ET
Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of ADX-914 for Atopic Dermatitis
WALTHAM, Mass. and DUBLIN, Oct. 27, 2022 /PRNewswire/ -- Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, and Horizon Therapeutics plc (Nasdaq: HZNP), today announced that the first patient has been dosed in a randomized, double-blind, placebo-controlled, Phase 2 multi-center proof-of-concept study in adult subjects to evaluate the safety and efficacy of ADX-914 in persistent, moderate-to-severe atopic dermatitis (AD). Q32 Bio and Horizon are developing ADX-914, a fully human anti-IL-7Rα antibody that re-regulates adaptive immune
Oct 27, 2022 08:30 am ET
Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of ADX-914 for Atopic Dermatitis
Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, and Horizon Therapeutics plc (Nasdaq: HZNP), today announced that the first patient has been dosed in a randomized, double-blind, placebo-controlled, Phase 2 multi-center proof-of-concept study in adult subjects to evaluate the safety and efficacy of
Oct 26, 2022 08:00 am ET
New Analysis of UPLIZNA® (inebilizumab-cdon) Phase 3 Trial Data Demonstrates Importance of Reducing Plasmablasts to Help Prevent Neuromyelitis Optica Spectrum Disorder (NMOSD) Attacks
Horizon Therapeutics plc (Nasdaq: HZNP) today announced new data from two analyses of the UPLIZNA Phase 3 pivotal trial being presented at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2022), Oct. 26-28 in Amsterdam. UPLIZNA is the first and only B-cell depleting monother
Oct 22, 2022 10:30 am ET
New Real-World Analysis of TEPEZZA® (teprotumumab-trbw) Use Indicates a Small Percentage of People Receive a Second Course of Treatment
Horizon Therapeutics plc (Nasdaq: HZNP) today announced new data from a real-world analysis of TEPEZZA presented at the 91st Annual Meeting of the ATA. TEPEZZA is the first and only medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of Thyroid Eye Disease (TED) – a serious, progressive and potentially vision-threatening rare autoimmune disease.1
Oct 13, 2022 08:00 am ET
Horizon Therapeutics plc to Present New Data on TEPEZZA® (teprotumumab-trbw) and Thyroid Eye Disease (TED) at the American Thyroid Association (ATA) Annual Meeting
Horizon Therapeutics plc (Nasdaq: HZNP) today announced new data will be presented at the 91st Annual Meeting of the American Thyroid Association (ATA 2022) in Montreal, October 19-23. TEPEZZA is the first and only medicine approved by the FDA for the treatment of TED. It is only approved in the U.S.
Oct 12, 2022 08:00 am ET
Horizon Therapeutics plc Announces New UPLIZNA® (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be presented at ECTRIMS 2022
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that new UPLIZNA analyses will be presented at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2022, Oct. 26-28. UPLIZNA is the first and only anti-CD19 B-cell-depleting humanized monoclonal antibody approved by the U.S. Food and Drug Administration (FDA) and European Commission (EC) for the treatment of adult patients with anti-aquaporin-4 (AQP4) antibody positive NMOSD.
Oct 06, 2022 10:03 am ET
Horizon Therapeutics plc Named to Newsweek’s 2022 Top 100 Most Loved Workplaces
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been named to Newsweek’s 2022 Top 100 Most Loved Workplaces® list for prioritizing respect, caring and appreciation for employees. The Newsweek list is the result of a collaboration with the Best Practice Institute (BPI), a leadership development and benchmark research company. The full list will be featured in the magazine’s Oct. 14 print edition and is currently available
Oct 06, 2022 08:00 am ET
Horizon Therapeutics plc to Release Third-Quarter 2022 Financial Results and Host Webcast on Nov. 2, 2022
Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it will release its third-quarter 2022 financial results on Wednesday, Nov. 2, 2022. Following the announcement, Horizon’s management will host a live webcast at 8 a.m. Eastern Time to review the Company’s financial and operating results.
Oct 02, 2022 11:15 am ET
New Data Reveal Molecular Drivers of Thyroid Eye Disease (TED) May Remain Activated In Patients with Low Clinical Activity Score (CAS)
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the presentation of new data defining molecular patterns in TED and further implicating the role of insulin-like growth factor-1 (IGF-1) in patients with low CAS. These data were presented during the American Academy of Ophthalmology Annual Meeting (AAO 2022), Sept. 30 – Oct. 3 in Chicago.
Sep 29, 2022 08:00 am ET
Horizon Therapeutics plc Completes Enrollment for Phase 4 Trial of TEPEZZA® (teprotumumab-trbw) in Adults with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED)
Horizon Therapeutics plc (Nasdaq: HZNP) announced that it has completed enrollment of its Phase 4 clinical trial (NCT04583735) evaluating TEPEZZA for the treatment of Thyroid Eye Disease (TED) in patients with a low Clinical Activity Score (CAS), also known as the TEPEZZA Chronic TED trial. CAS is a tool designed to evaluate inf
Sep 22, 2022 08:04 am ET
Horizon Therapeutics plc Expands Commitment to Education Equity, STEAM Careers and Historically Black Colleges and Universities, Adding Meharry Medical College as Horizon Scholars Partner
Horizon Therapeutics plc (Nasdaq: HZNP) today expanded its commitment to education equity, science, technology, engineering, arts and math (STEAM) careers and historically Black colleges and universities (HBCUs) through its Horizon Scholars program, which now includes a student at Meharry Medical College. The Horizon Scholars program provides scholarships to cover student debt burden while simultaneously offering professional mentorship, peer networking and internships and job opportunities for students.
Sep 21, 2022 08:04 am ET
Horizon Therapeutics plc Announces EB Research Partnership Receives 2022 Horizon Prize, Powered by MIT Solve
Horizon Therapeutics plc (Nasdaq: HZNP), in collaboration with MIT Solve, a marketplace for social impact innovation, is proud to announce the winning solution of this year’s Horizon Prize: Patient-Driven Data Platform for Rare Disease by
Sep 19, 2022 08:00 am ET
Horizon to Highlight Novel Insights in Gout Care During the American College of Rheumatology Convergence 2022
Horizon Therapeutics plc (Nasdaq: HZNP) today announced plans for a series of data presentations on its marketed and pipeline medicines, with a focus on continued efforts to advance the understanding and care of uncontrolled gout, during the American College of Rheumatology Convergence 2022 to be ho
Sep 16, 2022 09:00 am ET
Horizon Therapeutics plc Makes Founding Gift to Support the University of Notre Dame’s Patient Advocacy Initiative
Horizon Therapeutics plc (Nasdaq: HZNP) today announced it has made a founding, five-year gift to establish the University of Notre Dame’s Patient Advocacy Initiative in the College of Science. The gift will help advance Notre Dame’s Interdisciplinary Minor in Science and Patient Advocacy (MSPA) to further support training students interested in careers in advocacy for patients with rare and neglected diseases.
Sep 14, 2022 08:00 am ET
Data from the MIRROR Randomized Controlled Trial of KRYSTEXXA® (pegloticase) Injection with Methotrexate Published in Arthritis & Rheumatology
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the publication of data from the MIRROR randomized controlled clinical trial of KRYSTEXXA (pegloticase) injection with methotrexate, a commonly used immunomodulator, in Arthritis & Rheumatology [https://doi.org/10.1002/art.42335].
Sep 13, 2022 08:30 am ET
Horizon Therapeutics plc Joins the International Agency for the Prevention of Blindness (IAPB) to Encourage People to #LoveYourEyes this World Sight Day
Horizon Therapeutics plc (Nasdaq: HZNP) is teaming up with World Sight Day organizers IAPB to challenge five million people globally to pledge to have their vision checked before World Sight Day on Oct. 13. This year’s theme is #LoveYourEyes and calls on individuals to prioritize their eye health, while raising awareness about the challenges faced by the one billion people worldwide who cannot access or afford eye care services.
Sep 12, 2022 08:00 am ET
Horizon Therapeutics plc Announces Phase 2 Trial Evaluating Dazodalibep for the Treatment of Sjögren’s Syndrome Meets Primary Endpoint
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that its Phase 2 trial evaluating dazodalibep for the treatment of Sjögren’s syndrome met the primary endpoint in patients with moderate-to-high systemic disease activity as defined by the European Alliance of Associations for Rheumatology (EULAR) Sjögren's Syndrome Disease Activity Index (ESSDAI) score of ≥ 5. At Week 24, patients treated with dazodalibep achieved a 6.3-point reduction in their ESSDAI score and patients treated with placebo achieved a 4.1-point reduction, resulting in a statistically significant least squares mean differ
Sep 09, 2022 08:00 am ET
Horizon Therapeutics plc Announces $500 Million Share Repurchase Program
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that its Board of Directors authorized the repurchase of up to $500 million of the Company’s ordinary shares.
Sep 08, 2022 08:03 am ET
Horizon Therapeutics plc Ranks Number One on the Fortune Best Workplaces in Biopharma 2022 List
Horizon Therapeutics plc (Nasdaq: HZNP) today announced it has been named No. 1 on the Fortune Best Workplaces in Biopharma 2022 list in the large company category. This is the sixth consecutive year Horizon has been named to the list and the company’s third t
Aug 31, 2022 09:03 am ET
Horizon Therapeutics plc Named One of PEOPLE’s 100 Companies That Care®
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been named to the PEOPLE 100 Companies That Care list by PEOPLE and Great Place to Work. The list highlights the top U.S. companies that have succeeded in business while also demonstrating outstanding respect, care and c
Aug 29, 2022 04:00 am ET
Horizon Therapeutics plc Announces Plans to Expand its Development and Manufacturing Facility in Waterford, Ireland
Horizon Therapeutics plc (Nasdaq: HZNP) today announced it submitted a planning application to expand its development and manufacturing facility in Waterford, Ireland to add new drug substance biologics development and manufacturing capabilities. The planned facility would expand Horizon’s footprint, adding approximately 320,000 square feet to its current 44,000 square foot drug product (fill-finish) biologics facility, and would create approximately 350 jobs over time. Horizon anticipates providing additional details with respect to potential investment and timeline as the planning applicatio
Aug 25, 2022 08:00 am ET
Horizon Therapeutics plc to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Company will participate in the following conference in September:
Aug 15, 2022 08:00 am ET
Q32 Bio and Horizon Therapeutics Announce Collaboration in Autoimmune Diseases
WALTHAM, Mass. and DUBLIN, Aug. 15, 2022 /PRNewswire/ -- Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, and Horizon Therapeutics plc (Nasdaq: HZNP), today announced that they have entered into a collaboration and option agreement to develop ADX-914 for the treatment of autoimmune diseases.
Aug 15, 2022 08:00 am ET
Q32 Bio and Horizon Therapeutics Announce Collaboration in Autoimmune Diseases
Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, and Horizon Therapeutics plc (Nasdaq: HZNP), today announced that they have entered into a collaboration and option agreement to develop ADX-914 for the treatment of autoimmune diseases.
Aug 03, 2022 03:58 pm ET
Horizon Therapeutics Investor Alert: Kaplan Fox Investigates Potential Securities Fraud at Horizon Therapeutics Plc
Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Horizon Therapeutics plc ("Horizon Therapeutics” or the "Company”) (NASDAQ: HZNP), a biopharmaceutical company. If you are an investor of Horizon...
Aug 03, 2022 07:00 am ET
Horizon Therapeutics plc Reports Second-Quarter 2022 Financial Results and Revises Full-Year 2022 Net Sales and Adjusted EBITDA Guidance
Horizon Therapeutics plc (Nasdaq: HZNP) today announced second-quarter 2022 financial results and revised its full-year 2022 net sales and adjusted EBITDA guidance.
Jul 25, 2022 08:02 am ET
Horizon Therapeutics plc Named a Best Company for Multicultural Women
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been named by Seramount (formerly Working Mother media) to its Best Companies for Multicultural Women list. The list recognizes the top 80 U.S. companies that create and use best practices in hiring, retaining and promoting multicultural women.
Jul 21, 2022 08:00 am ET
Horizon Therapeutics plc Announces Inaugural #RAREis Global Advocate Grant Recipients
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the 30 patient advocacy organizations selected to receive the inaugural #RAREis Global Advocate Grant, which awards each a one-time grant of $5,000 to advance, ed
Jul 11, 2022 08:00 am ET
Horizon Therapeutics plc Announces Wanda Durant Has Joined Olympian Gail Devers to Raise Awareness of Thyroid Eye Disease Among Graves’ Disease Community
To commemorate Graves’ Disease Awareness Month this July, Horizon Therapeutics plc (Nasdaq: HZNP) is teaming up with all-star patient advocates, Wanda Durant and Gail Devers, to help others living with Graves’ disease know their risk for a separate, but related, condition called Thyroid Eye Disease (TED). TED is a serious, progressive, and potentially vision-threatening rare autoimmune disease.1
Jul 08, 2022 08:00 am ET
FDA Approves KRYSTEXXA® (pegloticase) Injection Co-Administered With Methotrexate, Expanding the Labeling to Help More People with Uncontrolled Gout Achieve a Complete Response to Therapy
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) expanding the labeling to include KRYSTEXXA® (pegloticase) injection co-administered with methotrexate, which will help more people with uncontrolled gout achieve a complete response to therapy.
Jul 07, 2022 08:00 am ET
Horizon Therapeutics plc to Release Second-Quarter 2022 Financial Results and Host Webcast on Aug. 3, 2022
Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it will release its second-quarter 2022 financial results on Wednesday, Aug. 3, 2022. Following the announcement, Horizon’s management will host a live webcast at 8 a.m. Eastern Time to review the Company’s financial and operating results.
Jun 24, 2022 12:30 pm ET
New Analysis Finds UPLIZNA® (inebilizumab) Effective Among European Populations with Neuromyelitis Optica Spectrum Disorder (NMOSD)
Horizon Therapeutics plc (Nasdaq: HZNP) today announced new findings from a post hoc analysis of the N-MOmentum Phase 3 pivotal trial of UPLIZNA supporting the medicine’s efficacy in Europeans living with NMOSD. These data are being presented during the 8th Congress of the European Academy
Jun 15, 2022 08:30 am ET
Horizon Therapeutics plc Submits Regulatory Filing for UPLIZNA® (inebilizumab) in Brazil
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has submitted a regulatory filing to the Brazil National Health Surveillance Agency (ANVISA) for UPLIZNA for the treatment of adult patients with anti-aquaporin-4 immunoglobulin G seropositive (AQP4-IgG+) neuromyelitis optica spectrum disorder (NMOSD).
Jun 15, 2022 07:45 am ET
Horizon Therapeutics plc Named One of the Fortune Best Workplaces in Chicago™
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been named to the Fortune Best Workplaces in Chicago 2022 list, ranking No. 3 in the large company category. The list includes 15 top large sized companies, as well as 35 best small-to-medium workplaces in th
Jun 11, 2022 10:00 am ET
Analysis of Pooled Data from TEPEZZA® (teprotumumab-trbw) Clinical Trials Reinforces Safety Profile in People with Thyroid Eye Disease (TED)
Horizon Therapeutics plc (Nasdaq: HZNP) today announced results of a new analysis examining rates of hyperglycemia among patients treated with TEPEZZA for TED compared to placebo in the Phase 2 and OPTIC Phase 3 clinical trials. These results were presented as part of the annual conference of the Endocrine Society, ENDO 2022, June 11-14 in Atlanta, G
Jun 09, 2022 08:00 am ET
Horizon Therapeutics plc Named a Top Company for Executive Women
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been recognized by Seramount (formerly Working Mother media) as a Top 75 Company for Executive Women.
Jun 06, 2022 04:30 pm ET
Horizon Therapeutics plc to Present at the Goldman Sachs 43rd Annual Global Health Care Conference
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Company will participate in the following conference in June:
Jun 02, 2022 08:00 am ET
Horizon Therapeutics plc to Highlight Data and Education on Thyroid Eye Disease (TED) at the Endocrine Society (ENDO) 2022 Annual Conference
Horizon Therapeutics plc (Nasdaq: HZNP) today announced new data will be presented at the Endocrine Society’s Annual Conference (ENDO 2022) in Atlanta, June 11-14, including:
Jun 01, 2022 08:00 am ET
Data Presented from the MIRROR Randomized Controlled Trial Demonstrate KRYSTEXXA® (pegloticase injection) Plus Methotrexate Resulted in Significant Improvement in Efficacy and Safety (Infusion Reactio
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the presentation of new KRYSTEXXA® (pegloticase injection) datasets on the primary endpoint results from the MIRROR randomized clinical trial and analyses of the pharmacokinetics of KRYSTEXXA plus methotrexate. Additional presentations by Horizon during
May 31, 2022 04:01 pm ET
Horizon Therapeutics plc Wins 2022 International CSR Excellence Award for #RAREis Adoption Fund
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the company has won an International Corporate Social Responsibility (CSR) Excellence Award for its partnership with Gift of Adoption to co-create the #RAREis Adoption Fund. As part of the award, Horizon will be formally recognized in the next
May 31, 2022 08:00 am ET
Analysis from the Phase 3 N-MOmentum Study Demonstrates the Effectiveness of UPLIZNA® (inebilizumab-cdon) Among Neuromyelitis Optica Spectrum Disorder Patients with Genetic Variations
Horizon Therapeutics plc (Nasdaq: HZNP) today announced data from the Phase 3 pivotal trial of UPLIZNA in NMOSD illustrating the treatment’s effectiveness among patients with different genetic make-ups, including those with certain variations associated with reduced response to conventional monoclonal antibody (mAb) therapies. These data are being presented during the
May 24, 2022 08:00 am ET
Horizon Therapeutics plc to Present MIRROR Randomized Controlled Trial Primary Endpoint Data at The EULAR 2022 European Congress of Rheumatology
Horizon Therapeutics plc (Nasdaq: HZNP) today announced a series of data presentations during The EULAR 2022 European Congress of Rheumatology, June 1 – 4 in Copenhagen.
May 17, 2022 08:00 am ET
Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab (HZN-7734) for the Treatment of Alopecia Areata
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the first patient has enrolled in a Phase 2, open-label, proof-of-concept trial to evaluate its development-stage medicine daxdilimab (HZN-7734), a potentially first-in-class, fully human monoclonal antibody targeting immunoglobulin-like transcript 7 (ILT7), to treat people with moderate-to-severe alopecia areata. Alopecia areata is a common, acute onset autoimmune disorder characterized by transient, non-scarring hair loss.1 It is the second most common form of alopecia and is associated with comorbidities including depression
May 16, 2022 09:00 am ET
Horizon Therapeutics plc Ranked Second in Overall Corporate Reputation in U.S. PatientView Survey of Patient Groups
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it ranked second in overall corporate reputation among U.S. patient groups who were familiar with the company and third among groups who reported working with the company. The results are based on PatientView’s annual
May 11, 2022 09:02 am ET
Horizon Therapeutics plc Announces Dara Mann as a Healthcare Businesswomen’s Association 2022 Rising Star
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that Dara Mann, vice president, marketing, ophthalmology, has been named a 2022 Healthcare Businesswomen’s Association (HBA) Rising Star. Mann was honored at the 2022 HBA Woman of the Year event yesterday.
May 11, 2022 08:30 am ET
Horizon Therapeutics plc Launches Letter-Writing Campaign to Empower Those Living with Thyroid Eye Disease (TED) to Confront the Condition Head On
For Mental Health Awareness Month and Healthy Vision Month in May, Horizon Therapeutics plc (Nasdaq: HZNP) is partnering with mental health expert and New York Times best-selling author, Lori Gottlieb, to highlight the emotional burden of living with TED – a serious, progressive, and potentially vision-threatening rare autoimmune condition.1
May 09, 2022 04:44 pm ET
Horizon Therapeutics and Chicago Sky Announce Multi-Year Partnership
Horizon Therapeutics (Nasdaq: HZNP) and the Chicago Sky today announced a multi-year partnership, which includes robust community programming as well as marketing and branding assets. As part of the partnership, Horizon will be the presenting sponsor of the newly unveiled Chicago Sky Basketball Academy, as well as one of twelve presenting sponsors of the Sky's social justice program, Beyond Basketball, which focuses on economic development, youth financial literacy, voting rights and food deserts. The partnership will also include rehabbing a basketball court in an underserved community each s
May 04, 2022 07:00 am ET
Horizon Therapeutics plc Reports First-Quarter 2022 Financial Results
Horizon Therapeutics plc (Nasdaq: HZNP) today announced first-quarter 2022 financial results and maintained its full-year 2022 net sales and adjusted EBITDA guidance.
May 03, 2022 09:15 am ET
Topline Data for Dazodalibep (HZN-4920) Meets Primary Endpoint in Rheumatoid Arthritis
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that its Phase 2, randomized, double-blinded, placebo-controlled trial of dazodalibep (HZN-4920) in rheumatoid arthritis (RA) met the primary endpoint.
May 02, 2022 04:05 pm ET
Horizon Therapeutics plc Launches #RAREis Global Advocate Grant Program to Support the Rare Disease Community
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the launch of the #RAREis Global Advocate Grant, a new program designed to support the rare disease community by providing financial assistance to U.S. and global patient advocacy groups working to advance, educate and address the needs of the community.
May 02, 2022 01:00 am ET
Horizon Therapeutics plc Receives European Commission (EC) Approval of UPLIZNA® (inebilizumab) for the Treatment of Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD)
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the European Commission (EC) approval of UPLIZNA® (inebilizumab) as monotherapy for the treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 immunoglobulin G seropositive (AQP4-IgG+), following the positive opinion adopted by the Committee for Medicinal Products for Human Use of the European Medicines Agency on 11th November, 2021.
Apr 27, 2022 08:01 am ET
Horizon Therapeutics plc Among Top Companies for Overall Corporate Reputation in 2021 Global PatientView Survey of Patient Groups Worldwide
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it ranked fifth in overall corporate reputation among patient groups that have worked directly with the company and seventh among patient groups who were familiar with the company. The results are based on PatientView’s annual survey of 2,150 patient groups.
Apr 19, 2022 09:00 am ET
Horizon Therapeutics and Massachusetts Institute of Technology (MIT) Solve Announce Second Annual Horizon Prize to Inspire Solutions that Improve the Quality of Life for the Global Rare Disease Commun
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the kickoff of the second annual global innovation challenge, The Horizon Prize powered by MIT Solve.
Apr 14, 2022 08:00 am ET
Horizon Therapeutics plc to Release First-Quarter 2022 Financial Results and Host Webcast on May 4, 2022
Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it will release its first-quarter 2022 financial results on Wednesday, May 4, 2022. Following the announcement, Horizon’s management will host a live webcast at 8 a.m. Eastern Time to review the Company’s financial and operating results.
Apr 11, 2022 09:20 am ET
Horizon Therapeutics plc Named One of the Fortune 100 Best Companies to Work For®
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been named one of Fortune’s 100 Best Companies to
Mar 31, 2022 08:30 am ET
New Analysis Finds UPLIZNA® (inebilizumab-cdon) Effective for People with Newly-Presenting Neuromyelitis Optica Spectrum Disorder (NMOSD)
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the presentation of a post-hoc analysis from the N-MOmentum Phase 3 pivotal trial of UPLIZNA, showing that the medicine was safe and effective in NMOSD patients who were treated with UPLIZNA after having only one attack. These data are being presented during a poster session at the
Mar 24, 2022 04:00 am ET
Horizon Therapeutics plc Named as One of the Best Workplaces in Ireland
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been recognized as one of the Best Workplaces in Ireland 2022 by Great Place to Work Ireland, ranking No. 9 in the medium company category.
Mar 07, 2022 08:00 am ET
Horizon Therapeutics plc Announces FDA Has Granted Priority Review of the Supplemental Biologics License Application (sBLA) for the Concomitant Use of KRYSTEXXA® (pegloticase injection) Plus Methotrex
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the U.S. Food and Drug Administration (FDA) granted priority review of the supplemental Biologics License Application (sBLA) to expand the label for KRYSTEXXA plus methotrexate, an immunomodulator commonly prescribed by rheumatologists. The Prescription Drug User Fee Act (PDUFA) action date is July 7, 2022.
Mar 02, 2022 08:00 am ET
Horizon Therapeutics plc Partners with Christine Ha, First Blind Contestant and Winner of MasterChef, to Amplify Her Unstoppable NMOSD Story
Horizon Therapeutics plc (Nasdaq: HZNP) is teaming up with Christine Ha, the first blind contestant on MasterChef and winner of the show’s third season, who has been living with neuromyelitis optica spectrum disorder (NMOSD) for more than 20 years. For NMO Awareness Month in March, Horizon and Ha are collaborating with the G
Mar 01, 2022 07:00 am ET
Horizon Therapeutics plc Reports Fourth-Quarter 2021 and Full-Year 2021 Financial Results; Announces Full-Year 2022 Guidance
Horizon Therapeutics plc (Nasdaq: HZNP) today announced fourth-quarter and record full-year 2021 financial results and provided full-year 2022 net sales and adjusted EBITDA guidance.
Feb 28, 2022 11:29 am ET
Horizon Therapeutics plc Launches #RAREis Representation Program to Elevate Global Rare Disease Equity
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the launch of the #RAREis Representation program, which expands Horizon’s #RAREis program to support advancing global equity in the rare disease community. The program is centered around a new section of the #RAREis website where individuals
Feb 28, 2022 09:00 am ET
Horizon Therapeutics plc Launches #RAREis Representation Program to Elevate Global Rare Disease Equity
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the launch of the #RAREis Representation program, which expands Horizon’s #RAREis program to support advancing global equity in the rare disease community. The program is centered around a new section of the #RAREis website where individuals are invited to provide feedback via a short survey on key issues related to rare disease equity, which will be used to inform long-term programming, toolkits and resources for the rare disease community.
Feb 23, 2022 08:00 am ET
Horizon Therapeutics plc Initiates Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating Teprotumumab for the Treatment of Active Thyroid Eye Disease (TED)
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the first patient has been enrolled in a Phase 3 clinical trial (OPTIC-J) in Japan evaluating teprotumumab for the treatment of active TED. TED is a serious, progressive and potentially vision-threatening rare autoimmune disease that can cause proptosis (eye bulging), diplopia (double vision), eye pain, redness and swelling.1 Teprotumumab, marketed under the brand name TEPEZZA in the United States (U.S.), was approved by the U.S. Food and Drug Administration (FDA) in January 2020 as the first and only medicine for TED, and

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.